How do you choose between axicabtagene ciloleucel and tisagenlecleucel in patients with follicular lymphoma for whom you are recommending CAR T-cell therapy?

This is an area of uncertainty. There are no head-to-head data to bring to bear, of course (and, if there were, you probably wouldn’t need to ask). The toxicity profile of the two cells is clearly different, with lower rates of severe toxicity with tisacel than with axicel. As neither product has be...

Personally, I think choosing between CAR-T products for follicular lymphoma is more challenging than in LBCL. In addition to axi-cel and tisa-cel, we have lisocabtagene maraleucel, which has the most recent approval for R/R FL but with shorter follow-up. Both ELARA (tisa-cel) and ZUMA-5 (axi-cel) al...

That is also challenging. I prefer axi-cel as I have more experience with it. I reserve tisa-cel for older patients or those with comorbidities. However, they both work very well.